Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

The traditional 6-9 month annual planning process in pharma is ill-equipped to handle accelerating consumer trends like AI-driven self-diagnosis and telemedicine. Brands must adopt a more agile strategy, using dedicated 'marketing R&D' budgets for continuous pilots to test and learn.

Related Insights

In today's fast-moving environment, a fixed 'long-term playbook' is unrealistic. The effective strategy is to set durable goals and objectives but build in the expectation—and budget—to constantly pivot tactics based on testing and learning.

Committing to a quarterly roadmap is futile when the AI landscape and customer needs change daily. Instead of detailed feature plans, leaders should set broad strategic objectives and focus on short-term, validated learning cycles. This approach builds a foundation that can adapt to rapid market shifts.

The traditional pharma leadership model focused on minimizing risk through tight, linear control is no longer competitive. The future requires a shift to agile coordination, allowing leaders to reallocate priorities quickly in a data-driven, connected way.

The rapid pace of AI makes traditional, static marketing playbooks obsolete. Leaders should instead foster a culture of agile testing and iteration. This requires shifting budget from a 70-20-10 model (core-emerging-experimental) to something like 60-20-20 to fund a higher velocity of experimentation.

The classic closed-loop model informing annual strategy is obsolete. Advanced analytics enable a "multi-loop" system where insights can immediately change sales rep talking points (execution loop) or marketing journeys (orchestration loop) without waiting for the next strategy cycle.

In the fast-moving AI sector, quarterly planning is obsolete. Leaders should adopt a weekly reassessment cadence and define "boundaries for experimentation" rather than rigid goals. This fosters unexpected discoveries that are essential for staying ahead of competitors who can leapfrog you in weeks.

The pandemic acted as an unavoidable wake-up call, compelling the slow-moving pharmaceutical industry to rapidly adopt digital engagement models and embrace a more agile, customer-focused commercial approach, achieving in one year what would have taken ten.

Detailed annual plans quickly become obsolete. Instead, establish high-level strategic themes for the year, like 'Act Bigger Than We Are.' This provides a clear direction while empowering the team to creatively contribute and remain agile enough to jump on unforeseen opportunities without breaking a rigid plan.

The rapid pace of change in AI renders long-term strategic planning ineffective. With foundational technology shifts occurring quarterly, companies must adopt a fluid approach. Strategy should focus on core principles and institutional memory, while remaining flexible enough to integrate new tech and iterate on tactics constantly.

The technical and data preparation for an AI-driven healthcare world will take pharma companies 18-24 months. If they wait until AI tools are mainstream, they will face an insurmountable two-year gap to catch up, a period in which they will become irrelevant.

The Annual Brand Planning Cycle Is Too Slow for Today's Rapid Shifts in Patient Behavior | RiffOn